B of A Securities Downgrades Sage Therapeutics to Underperform, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Tazeen Ahmad downgraded Sage Therapeutics (SAGE) from Neutral to Underperform and reduced the price target from $24 to $14.
April 17, 2024 | 1:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics was downgraded from Neutral to Underperform by B of A Securities, with a price target reduction from $24 to $14.
The downgrade by a major analyst and significant reduction in price target are likely to negatively impact investor sentiment and could lead to a decrease in SAGE's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100